Treatment of hormone-refractory prostate cancer, HRPC, remains challenging.

Abstract

To the editor, Treatment of hormone-refractory prostate cancer, HRPC, remains challenging. In the journal Medical Oncology, we read with interest the article written by Nelius et al. [1] in which they concluded metronomic cyclophosphamide may be beneficial for patients with docetaxel-resistant HRPC. In this pilot study, 17 patients who failed docetaxel were… (More)
DOI: 10.1007/s12032-009-9249-1

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics